Tie-2 Activator Formulation Zero-Order Release for Intraocular Pressure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations for treating elevated intraocular pressure and glaucoma often fail to effectively stabilize the vasculature associated with the trabecular meshwork, leading to inadequate reduction of intraocular pressure and potential vision loss.
Innovation Solution
Development of pharmaceutical compositions containing Tie-2 activators, specifically compounds that inhibit HPTPβ, which are formulated to provide a zero-order release rate, stabilizing the vasculature and enhancing aqueous humor outflow by promoting Tie-2 phosphorylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical formulations are used, then the formulation can be administered, but the vasculature is not effectively stabilized and intraocular pressure is not adequately reduced
Solution Approach 1:
The patent employs parameter changes by modifying the release kinetics of the Tie-2 activator to achieve zero-order release. This controlled release parameter ensures stable plasma concentrations and sustained vascular stabilization, directly addressing the inadequate efficacy of conventional formulations that fail to maintain therapeutic levels sufficient for reducing intraocular pressure and stabilizing vasculature.
2Duration of action of moving object
If the Tie-2 activator is released rapidly, then the initial therapeutic effect is strong, but the duration of action is insufficient and pressure control is inadequate
Solution Approach 1:
The patent implements continuity of useful action through zero-order release kinetics, which provide continuous and constant release of the Tie-2 activator over an extended period. This continuous release mechanism maintains sustained therapeutic concentrations, ensuring prolonged vascular stabilization and consistent intraocular pressure control, thereby resolving the contradiction between duration of action and rate of pressure reduction.
3Reliability
If the formulation uses conventional release kinetics, then the formulation is simple, but the release rate is not controlled and therapeutic levels are not maintained
Solution Approach 1:
The patent applies parameter changes by transitioning from conventional first-order release kinetics to zero-order release kinetics. This fundamental change in the release parameter enables controlled and predictable delivery of the Tie-2 activator, maintaining therapeutic levels reliably while managing formulation complexity through established controlled-release technologies.
Data Source
AI summary
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTPβ. Further disclosed are formulations to increase the efficacy of the compounds that activate Tie-2 and inhibit HPTPβ.